Biologic drugs are complex, large-molecule therapies derived from living cells, offering targeted treatment for a wide range of diseases. Biosimilar are highly similar versions of approved biologics, designed to match their safety, efficacy, and quality profiles. The development of biologics and biosimilar involves sophisticated manufacturing processes and strict regulatory oversight. These therapies have transformed treatment approaches for conditions such as rheumatoid arthritis, cancer, and multiple sclerosis. Research in this area aims to improve cost-effectiveness, expand patient access, and develop innovative delivery systems. Understanding the nuances of immunogenicity, manufacturing consistency, and clinical equivalence is vital for success in this field.
Subtracts:
Related Conferences:
World Congress on Pharmacology & Toxicology (WCPT) | International Conference on Clinical Pharmacology & Therapeutics (ICCPT) | Global Summit on Drug Discovery and Development (GSDDD) | European Conference on Toxicology & Applied Pharmacology (ECTAP) | International Symposium on Experimental and Clinical Toxicology (ISECT)
Related Associations:
International Union of Basic and Clinical Pharmacology (IUPHAR) | British Pharmacological Society (BPS) | American Society for Pharmacology and Experimental Therapeutics (ASPET) | European Society of Toxicology (EUROTOX) | Society of Toxicology (SOT) | Asia Pacific Association of Pharmacologists (APAP) | Federation of Asian Pharmacological Societies (FAPS) | International Society for the Study of Xenobiotics (ISSX)
All accepted abstracts will be published in respective Allied Academies Journals.
Abstracts will be provided with Digital Object Identifier by
